EPM
TCRT icon

Equitec Proprietary Markets’s Alaunos Therapeutics TCRT Stock Holding History

Equitec Proprietary Markets’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7
Closed -$644 – 142
2023
Q1 		$644 Hold
7
– – ﹤0.01% 133
2022
Q4 		$664 Hold
7
– – ﹤0.01% 172
2022
Q3 		$2K Hold
7
– – ﹤0.01% 217
2022
Q2 		$1K Hold
7
– – ﹤0.01% 240
2022
Q1 		$1K Hold
7
– – ﹤0.01% 231
2021
Q4 		$1K Buy
+7
New +$1.54K ﹤0.01% 432
2021
Q3 		– Sell
-80
Closed -$24.5K – 290
2021
Q2 		$32K Buy
+80
New +$37.3K 0.01% 196
2020
Q4 		$13K Sell
33
-13
-28% -$5.17K ﹤0.01% 109
2020
Q3 		$17K Buy
+46
New +$20.3K 0.01% 84
2020
Q1 		$16K Buy
+30
New +$15.5K 0.01% 250
2018
Q2 		– Sell
-136
Closed -$86.2K – 73
2018
Q1 		$80K Sell
136
-291
-68% -$181K 0.02% 51
2017
Q4 		$265K Buy
427
+24
+6% +$17.2K 0.08% 46
2017
Q3 		$371K Buy
403
+175
+77% +$155K 0.09% 54
2017
Q2 		$212K Buy
+228
New +$224K 0.05% 79
2017
Q1 		– Sell
-351
Closed -$327K – 111
2016
Q4 		$281K Buy
351
+284
+424% +$256K 0.01% 80
2016
Q3 		$57K Buy
67
+40
+148% +$32.2K ﹤0.01% 117
2016
Q2 		$22K Buy
+27
New +$29.4K ﹤0.01% 129

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Equitec Proprietary Markets's TCRT Position: Q2 2023 in Review

Equitec Proprietary Markets sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 7 shares — an estimated $644 sold.

Equitec Proprietary Markets first reported a position in TCRT in Q2 2016 and held it in 17 quarters. The position peaked at $371K in Q3 2017. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • Equitec Proprietary Markets reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Equitec Proprietary Markets sold 7 Alaunos Therapeutics shares in Q2 2023, an estimated $644.
  • Equitec Proprietary Markets first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 17 quarters.
  • Equitec Proprietary Markets's Alaunos Therapeutics position peaked at $371K in Q3 2017.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Equitec Proprietary Markets's 13F filing for Q2 2023, filed 12 Jul 2023.